세계의 특발성 폐섬유증 시장 : 약물 유형별, 투여 경로별, 유통 채널별, 지역별, 국가별 분석, 시장 인사이트, 예측

Executive Summary

Azoth Analytics has released a research report titled "Idiopathic Pulmonary Fibrosis Market (2023 Edition)" which provides a complete analysis of the global Idiopathic Pulmonary Fibrosis industry in terms of market segmentation by Drug Type (Pirfenidone, Nintedanib, Others), Route of Administration (Oral, Parenteral, Others) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel).

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 11 countries (United States, Canada, Mexico, United Kingdom, Germany, France, Italy, China, India, Japan, South Korea). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

The research study also looks at the market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

During the forecast period, 2024-2029, the Global Idiopathic Pulmonary Fibrosis market is expected to expand at a CAGR of 46.3%. The Global Idiopathic Pulmonary Fibrosis Market is expected to generate USD 10.64 billion by the end of 2029, up from USD 4.39 billion in 2022.

IPF is a life-threatening illness and is both progressive and incurable. Treatments can manage symptoms, limit disease progression, and improve quality of life. Pirfenidone and nintedanib are authorized IPF treatments that slow fibrosis. Severe instances may require lung transplants.

Although IPF is considered a rare disease, its incidence has increased over time. It is estimated that 13 to 20 people per 100,000 are affected globally. The prevalence is higher in older age categories, and the disease is diagnosed more frequently in people over 50. IPF affects both men and women, although men are slightly more susceptible. Ongoing research and clinical trials are investigating novel treatments and potential IPF therapies. Among these are antifibrotic agents, immunomodulatory drugs, and other novel therapeutic approaches that target different pathways implicated in the fibrotic process.

IPF patients need medical follow-ups. Work with interstitial lung disease specialists to create a specific treatment plan and support methods. IPF is characterized by a persistent dry cough, shortness of breath (especially during physical activity), exhaustion, and chest pain. These symptoms typically develop and worsen over time.

Scope of the Report:

• The report analyses the Idiopathic Pulmonary Fibrosis Market by Value (USD Million).
• The report presents the analysis of the Idiopathic Pulmonary Fibrosis Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
• The report analyses the Idiopathic Pulmonary Fibrosis Market by Drug Type (Pirfenidone, Nintedanib, Other drugs).
• The report analyses the Idiopathic Pulmonary Fibrosis Market by Route of Administration (Oral, Parenteral, Other ROA).
• The report analyses the Idiopathic Pulmonary Fibrosis Market by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel).
• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.
• Also, the major opportunities, trends, drivers and challenges of the industry have been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Boehringer Ingelheim, F. Hoffmann-La Roche AG, Cipla Ltd., Shionogi & Co., Ltd., Bristol-Myers Squibb Co., United Therapeutics, FibroGen, Inc., Pliant Therapeutics, Galecto Inc., CSL Behring

Table of Contents

1. Market Background

• 1.1 Scope and Product Outlook
• 1.2 Executive Summary
• 1.3 Research Methodology

2. Strategic Recommendations

• 2.1 Enhancing R&D operations for the development of novel treatments
• 2.2 Improving access to treatment

3. Global Idiopathic Pulmonary Fibrosis Market: Historic and Forecast

• 3.1 Impact Analysis of Macro Economic Factors on Idiopathic Pulmonary Fibrosis Market
• 3.2 Most bothersome IPF symptom
• 3.3 Idiopathic Pulmonary Fibrosis diagnosed prevalent cases
• 3.4 Competitive Landscape for IPF Drugs in Pipeline
• 3.5 Chronic Cough due to IPF
• 3.6 Idiopathic Pulmonary Fibrosis: Fact Sheet
• 3.7 Pathophysiology of Chronic Cough due to IPF
• 3.8 Comorbidities Associated with Chronic Cough in IPF
• 3.9 Global Idiopathic Pulmonary Fibrosis Market: Dashboard
• 3.10 Global Idiopathic Pulmonary Fibrosis Market: Market Value Assessment, 2018-2028 (USD Million)
• 3.11 Impact of COVID-19 on Global Idiopathic Pulmonary Fibrosis Market
• 3.12 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
  • 3.12.1 Global Idiopathic Pulmonary Fibrosis Market, By Drug Type Type Overview
  • 3.12.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
  • 3.12.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
  • 3.12.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
• 3.13 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
  • 3.13.1 Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
  • 3.13.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
  • 3.13.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
  • 3.13.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
• 3.14 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
  • 3.14.1 Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
  • 3.14.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies By Value, 2018H-2028F (USD Million & CAGR)
  • 3.14.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
  • 3.14.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)

4. Global Idiopathic Pulmonary Fibrosis Market, Regional Analysis

• 4.1 Regional Coverage of the Study

5. Americas Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

• 5.1 Americas Idiopathic Pulmonary Fibrosis Market: Snapshot
• 5.2 Americas Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
• 5.3 Americas Idiopathic Pulmonary Fibrosis Market: Key Factors
• 5.4 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
  • 5.4.1 Americas Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
  • 5.4.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.4.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.4.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
• 5.5 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
  • 5.5.1 Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
  • 5.5.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.5.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.5.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
• 5.6 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
  • 5.6.1 Americas Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
  • 5.6.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.6.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.6.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)
• 5.7 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Country
  • 5.7.1 United States Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
    • 5.7.1.1 United States Idiopathic Pulmonary Fibrosis Market, By Drug Type
    • 5.7.1.2 United States Idiopathic Pulmonary Fibrosis Market, By Route of Administration
    • 5.7.1.3 United States Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
  • 5.7.2 Canada Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
    • 5.7.2.1 Canada Idiopathic Pulmonary Fibrosis Market, By Drug Type
    • 5.7.2.2 Canada Idiopathic Pulmonary Fibrosis Market, By Route of Administration
    • 5.7.2.3 Canada Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
  • 5.7.3 Rest of Americas Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
    • 5.7.3.1 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Drug Type
    • 5.7.3.2 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration
    • 5.7.3.3 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration

6. Europe Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

• 6.1 Europe Idiopathic Pulmonary Fibrosis Market: Snapshot
• 6.2 Europe Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
• 6.3 Europe Idiopathic Pulmonary Fibrosis Market: Key Factors
• 6.4 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
  • 6.4.1 Europe Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
  • 6.4.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
  • 6.4.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
  • 6.4.4 Europe Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
• 6.5 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
  • 6.5.1 Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
  • 6.5.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
  • 6.5.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
  • 6.5.4 Europe Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
• 6.6 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
  • 6.6.1 Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
  • 6.6.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
  • 6.6.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
• 6.7 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Country
  • 6.7.1 France Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
    • 6.7.1.1 France Idiopathic Pulmonary Fibrosis Market, By Drug Type
    • 6.7.1.2 France Idiopathic Pulmonary Fibrosis Market, By Route of Administration
    • 6.7.1.3 France Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
  • 6.7.2 United Kingdom Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
    • 6.7.2.1 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Drug Type
    • 6.7.2.2 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Route of Administration
    • 6.7.2.3 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
  • 6.7.3 Italy Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
    • 6.7.3.1 Italy Idiopathic Pulmonary Fibrosis Market, By Drug Type
    • 6.7.3.2 Italy Idiopathic Pulmonary Fibrosis Market, By Route of Administration
    • 6.7.3.3 Italy Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
  • 6.7.4 Spain Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
    • 6.7.4.1 Spain Idiopathic Pulmonary Fibrosis Market, By Drug Type
    • 6.7.4.2 Spain Idiopathic Pulmonary Fibrosis Market, By Route of Administration
    • 6.7.4.3 Spain Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
  • 6.7.5 Germany Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
    • 6.7.5.1 Germany Idiopathic Pulmonary Fibrosis Market, By Drug Type
    • 6.7.5.2 Germany Idiopathic Pulmonary Fibrosis Market, By Route of Administration
    • 6.7.5.3 Germany Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
  • 6.7.6 Rest of Europe Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
    • 6.7.6.1 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Drug Type
    • 6.7.6.2 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration
    • 6.7.6.3 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

7. Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

• 7.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Snapshot
• 7.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
• 7.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Key Factors
• 7.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
  • 7.4.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
  • 7.4.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.4.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.4.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
• 7.5 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
  • 7.5.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
  • 7.5.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.5.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.5.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
• 7.6 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
  • 7.6.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
  • 7.6.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.6.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.6.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)
• 7.7 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Country
  • 7.7.1 China Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
    • 7.7.1.1 China Idiopathic Pulmonary Fibrosis Market, By Drug Type
    • 7.7.1.2 China Idiopathic Pulmonary Fibrosis Market, By Route of Administration
    • 7.7.1.3 China Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
  • 7.7.2 Japan Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
    • 7.7.1.1 Japan Idiopathic Pulmonary Fibrosis Market, By Drug Type
    • 7.7.1.2 Japan Idiopathic Pulmonary Fibrosis Market, By Route of Administration
    • 7.7.1.3 Japan Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
  • 7.7.3 South Korea Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
    • 7.7.3.1 South Korea Idiopathic Pulmonary Fibrosis Market, By Drug Type
    • 7.7.3.2 South Korea Idiopathic Pulmonary Fibrosis Market, By Route of Administration
    • 7.7.3.3 South Korea Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
  • 7.7.4 India Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
    • 7.7.4.1 India Idiopathic Pulmonary Fibrosis Market, By Drug Type
    • 7.7.4.2 India Idiopathic Pulmonary Fibrosis Market, By Route of Administration
    • 7.7.4.3 India Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
  • 7.7.5 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
    • 7.7.5.1 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Drug Type
    • 7.7.5.2 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Route of Administration
    • 7.7.5.3 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

8. Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

• 8.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Snapshot
• 8.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
• 8.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Key Factors
• 8.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
  • 8.4.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
  • 8.4.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
  • 8.4.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
  • 8.4.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
• 8.5 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
  • 8.5.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
  • 8.5.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
  • 8.5.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
  • 8.5.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
• 8.6 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
  • 8.6.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Distribution Channel: Overview
  • 8.6.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
  • 8.6.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
  • 8.6.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)

9. Market Dynamics

• 9.1 Impact Assessment of Market Dynamics on the Global Idiopathic Pulmonary Fibrosis Market
• 9.2 Drivers
• 9.3 Restraints
• 9.4 Trends

10. Industry Ecosystem Analysis

• 10.1 Macro-Economic Factor Assessment
• 10.2 Porter's Five Forces Model

11. Competitive Positioning

• 11.1 Companies' Product Positioning
• 11.2 Market Position Matrix
• 11.3 Market Share Analysis of Idiopathic Pulmonary Fibrosis Market
• 11.4 Company Profiles
  • 11.4.1 Boehringer Ingelheim
  • 11.4.2 F. Hoffmann-La Roche AG
  • 11.4.3 Cipla Ltd.
  • 11.4.4 Shionogi & Co., Ltd.
  • 11.4.5 Bristol-Myers Squibb Co.
  • 11.4.6 United Therapeutics
  • 11.4.7 FibroGen, Inc.
  • 11.4.8 Pliant Therapeutics
  • 11.4.9 Galecto Inc.
  • 11.4.10 CSL Behring